Top Abstract Purchase Related
Home
>
Node
>
Subnode

Selective elimination of atherogenic lipoproteins using dextran-sulfate cellulose. Experiences in 2 patients with heterozygote familial hypercholesterolemia

Riesen, W.F.; Descoeudres, C.; Mordasini, R.; Girod, M.A.

Schweizerische Medizinische Wochenschrift 119(2): 55-58

1989

ISSN/ISBN: 0036-7672
PMID: 2464848
Document Number: 326986
Extracorporeal elimination of atherogenic lipoproteins with dextran-sulfate-cellulose for lowering of plasma cholesterol levels was tested in 2 patients with familial heterozygous hypercholesterolemia (untreated cholesterol values 12.9 +/- 1.5 and 12.5 +/- 1.2 respectively) in a longterm experiment. One patient was treated weekly for a period of 36 weeks and the other at fourteen days' intervals with simultaneous administration of 40 mg/day Simvastatin (synvinolin, MSD) for 8 weeks. The mean reduction in total cholesterol concentration was 41% in the first case and 54% in the second (combination with Simvastatin). The therapy was well tolerated without side effects.

Document emailed within 1 workday
Secure & encrypted payments

Jansen, S.; Zambrana, J.L.; López Miranda, J.; Blanco, A.; Blanco, J.; Jiménez Perepérez, J.A.; Espino, A.; Pérez Jiménez, F. 1995: Possible relationship between overweightness and prevalence of hyperlipemia in the children of patients with heterozygote familial hypercholesterolemia and combined familial hyperlipemia Medicina Clinica 105(3): 85-88
Dairou, F.; Rottembourg, J.; de Gennes, J.L.; Assogba, U.; Bruckert, E.; Jacobs, C.; Truffert, J. 1988: Comparison between treatments of severe forms of familial hypercholesterolemia by total plasma exchange and selective removal of low density lipoproteins (LDLapheresis) Presse Medicale 17(33): 1679-1682
Chen, K.; Mu, Y.-m.; Wang, B.-a.; Guo, Q.-h.; Lü, Z.-h.; Dou, J.-t.; Lu, J.-m. 2006: A compound heterozygote family of familial hypercholesterolemia due to new mutations Zhonghua Nei Ke Za Zhi 45(9): 725-729
Iarovaia, E.B.; Rostapshova, T.V.; Susekov, A.V.; Kukharchuk, V.V. 1993: The choice of the optimal regimen for apheresis of the low-density lipoproteins in patients with familial hypercholesterolemia by using mathematical modelling Kardiologiia 33(10): 50
Taniguchi, Y.; Yorioka, N.; Kumagai, J.; Ogata, S.; Sakikubo, E.; Yamakido, M. 1999: Dextran sulfate-cellulose adsorption in the management of a myeloma patient with renal amyloidosis International Journal of Artificial Organs 22(5): 349-350
Ros Rahola, E. 1993: The apheresis of low-density lipoproteins in homozygous familial hypercholesterolemia Medicina Clinica 100(3): 117-118
Fedele, F. 2003: DEAE-Dextran in the treatment of primary hypercholesterolemia and/or hypercholesterolemia combined with hypertriglyceridemia. a multicentric randomized study on the efficacy of DEAE-Dextran compared with Cholestyramine La Clinica Terapeutica 154(4): 231-236
Napoli, C.; Postiglione, A.; Scarpato, N.; Corso, G.; Ambrosio, G.; Condorelli, M.; Mancini, M.; Chiariello, M. 1996: LDL oxidation in homozygous familial hypercholesterolemia: effects of selective LDL-apheresis treatment Cardiologia 41(5): 435-439
Konovalov, G.A.; Pokrovskiĭ, S.N.; Trakht, I.N.; Bokchubaev, E.; Volkova, E.I.; Kukharchuk, V.V. 1991: The plasmoimmunosorption of low-density lipoproteins in the treatment of patients with hereditary hypercholesterolemia Terapevticheskii Arkhiv 63(7): 65-70
Vasil'chenko, E.M.; Beĭko, V.A.; Tymchishin, P.N.; Karpov, R.S. 1989: Changes in the rosette-forming capacity of peripheral blood lymphocytes in patients with ischemic heart disease after administration of atherogenic lipoproteins Kardiologiia 29(2): 53-56
Shiomi, M.; Ito, T.; Watanabe, Y. 1987: Hypercholesterolemia and atherosclerosis in the WHHL rabbit, an animal model of familial hypercholesterolemia Progress in Clinical and Biological Research 229: 35-40
Vasil'chenko, E.M.; Beĭko, V.A.; Karpov, R.S.; Kanskaia, N.V. 1989: Characteristics of the action of modified atherogenic-class lipoproteins on the functional activity of peripheral blood lymphocytes in patients with ischemic heart disease Terapevticheskii Arkhiv 61(9): 56-59
Balestrieri, G.P.; Maffi, V.; Sleiman, I.; Spandrio, S.; Di Stefano, O.; Salvi, A.; Scalvini, T. 1996: Fish oil supplementation in patients with heterozygous familial hypercholesterolemia Recenti Progressi in Medicina 87(3): 102-105
Lopukhin, I.M.; Andrianova, I.P.; Rabovskiĭ, A.B.; Nalivaĭko, E.S.; Kulaev, D.V. 1986: Affinity hemosorbent for the binding of atherogenic lipoproteins Kardiologiia 26(10): 54-57
Krapivner, S.R.; Malyshev, P.P.; Rozhkova, T.A.; Potaraus, A.B.; Kukharchuk, V.V.; Bochkov, V.N. 2000: Application of DNA analysis for differential diagnosis of familial hypercholesterolemia and familial defect of apolipoprotein b-100 Terapevticheskii Arkhiv 72(4): 9-12
Freiberger, T.; Kuhrová, V.; Kozák, L.; Soska, V.; Pekarík, V.; Mĕrínská, L.; Fajkusová, L.; Francová, H. 1998: Direct detection of mutations in the LDL receptor gene in patients with familial hypercholesterolemia Casopis Lekaru Ceskych 137(24): 750-752
Cefalù, A.B.; Emmanuele, G.; Marino, G.; Fiore, B.; Caldarella, R.; Vivona, N.; Noto, D.; Barbagallo, C.M.; Costa, S.; Gueli, M.C.; Bertolini, S.; Notarbartolo, A.; Travali, S.; Averna, M.R. 2001: Effectiveness of screening for known mutations in Sicilian patients with "probable" familial hypercholesterolemia Nutrition Metabolism and Cardiovascular Diseases: Nmcd 11(6): 394-400
Mertz, D.P.; Göhmann, E.; Ostertag, J. 1981: Differential use of apolipoproteins and lipoproteins as discriminators for atherogenic risk Die Medizinische Welt 32(43): 1611-1615
Meshkov, A.N.; Stambol'skiĭ, D.V.; Krapivner, S.R.; Bochkov, V.N.; Kukharchuk, V.V.; Malyshev, P.P. 2004: Low density lipoprotein receptor gene mutations in patients with clinical diagnosis of familial hypercholesterolemia Kardiologiia 44(9): 58-61
Ferrières, J.; Lambert, J.; Lussier-Cacan, S.; Davignon, J. 1995: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation Circulation 92(3): 290-295